Saltar al contenido
Merck

MRTF-A controls vessel growth and maturation by increasing the expression of CCN1 and CCN2.

Nature communications (2014-06-10)
Rabea Hinkel, Teresa Trenkwalder, Björn Petersen, Wira Husada, Florian Gesenhues, Seungmin Lee, Ewald Hannappel, Ildiko Bock-Marquette, Daniel Theisen, Laura Leitner, Peter Boekstegers, Czeslaw Cierniewski, Oliver J Müller, Ferdinand le Noble, Ralf H Adams, Christine Weinl, Alfred Nordheim, Bruno Reichart, Christian Weber, Eric Olson, Guido Posern, Elisabeth Deindl, Heiner Niemann, Christian Kupatt
RESUMEN

Gradual occlusion of coronary arteries may result in reversible loss of cardiomyocyte function (hibernating myocardium), which is amenable to therapeutic neovascularization. The role of myocardin-related transcription factors (MRTFs) co-activating serum response factor (SRF) in this process is largely unknown. Here we show that forced MRTF-A expression induces CCN1 and CCN2 to promote capillary proliferation and pericyte recruitment, respectively. We demonstrate that, upon G-actin binding, thymosin ß4 (Tß4), induces MRTF translocation to the nucleus, SRF-activation and CCN1/2 transcription. In a murine ischaemic hindlimb model, MRTF-A or Tß4 promotes neovascularization, whereas loss of MRTF-A/B or CCN1-function abrogates the Tß4 effect. We further show that, in ischaemic rabbit hindlimbs, MRTF-A as well as Tß4 induce functional neovascularization, and that this process is inhibited by angiopoietin-2, which antagonizes pericyte recruitment. Moreover, MRTF-A improves contractile function of chronic hibernating myocardium of pigs to a level comparable to that of transgenic pigs overexpressing Tß4 (Tß4tg). We conclude that MRTF-A promotes microvessel growth (via CCN1) and maturation (via CCN2), thereby enabling functional improvement of ischaemic muscle tissue.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Anticuerpo anti-proteoglucano sulfato de condroitina NG2, Chemicon®, from rabbit